The pharmaceutical and biotechnology industries are increasingly dependent on strategic partnerships to accelerate innovation, expand market access, strengthen pipelines, and maximize the value of promising assets. However, identifying the right partner is often more complex than simply finding a company operating in the same therapeutic area. Organizations need to evaluate scientific capabilities, technology platforms, commercial…

Innovation in the life sciences rarely follows a straight line from lab bench to pharmacy shelf. A large share of today’s most successful therapies did not originate within the walls of the companies that ultimately commercialized them. More often, they were discovered by small biotech firms, university research groups, or academic institutions, and later transferred…

The zika virus market has drawn sustained attention from researchers, drug developers, and public health bodies since the virus first caused sporadic infections in Africa and Asia between the 1960s and 1980s. Since 2007, outbreaks have been reported across Asia, the Pacific, the Americas, and Africa, and the disease continues to shape research priorities across…

Anemia remains one of the most common yet under-addressed complications faced by cancer patients undergoing chemotherapy. Triggered largely by myelosuppression and, in some cases, renal dysfunction caused by agents like cisplatin and docetaxel, this condition—known as chemotherapy induced anemia—affects a substantial share of oncology patients and significantly diminishes their quality of life through fatigue, cardiovascular…

Fear of being trapped, of losing control in public, of not being able to escape — that’s the daily reality for people living with agoraphobia. It’s a condition that rarely makes headlines, but the business built around treating it is quietly gathering momentum. A new forecast from DelveInsight lays out where this space is headed…

Rare disease markets rarely stay static for long, and McCune-Albright syndrome is no exception. This genetic disorder — recognized by its hallmark trio of fibrous dysplasia, café-au-lait skin patches, and endocrine disturbances like early puberty — affects patients in strikingly different ways depending on the extent of the underlying mutation. That variability makes forecasting the…

The pharmaceutical industry rarely sees a therapeutic class move as quickly from niche diabetes treatment to global commercial phenomenon. That is precisely what has happened with GLP-1-based therapies, and the numbers behind the glp-1 market size across the US, EU4, UK, and Japan through 2036 reflect a franchise still in its early innings despite years…

Coxsackievirus infections represent a critical challenge in global infectious disease management, affecting millions of individuals annually with manifestations ranging from mild febrile illness to severe complications such as viral myocarditis, meningitis, and hand-foot-mouth disease. These infections are caused by Coxsackieviruses, which are members of the Enterovirus genus within the Picornaviridae family, comprising two main groups:…

The pharmaceutical and biotechnology industries are undergoing significant transformation as companies navigate complex clinical development pathways, evolving regulatory requirements, changing healthcare economics, increasing competition, and rising expectations for innovation. In this environment, strategic decision-making requires more than conventional market research. Companies need reliable intelligence, specialized industry expertise, and actionable recommendations that can translate complex data…

Surgeons around the world are leaning on smarter tissue-joining technology more than ever, and the numbers tell the story. Valued at USD 4,159.35 million in 2025, the anastomosis device market is projected to climb to USD 6,922.84 million by 2034, expanding at a CAGR of 5.86% between 2026 and 2034. Behind this momentum lies a…